文献速递浆细胞疾病血栓与止血

卡非佐米或硼替佐米联合来那度胺和地塞米松治疗新诊断多发性骨髓瘤的血栓栓塞风险:比较系统评价与Meta分析

Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis.
PubMed 文献 · Am J Hematol · 2024-03-15

该系统评价与Meta分析比较KRd与VRd方案治疗新诊断多发性骨髓瘤的血栓栓塞风险,纳入1项随机对照试验和5项回顾性队列研究,共分析2304例患者VTE事件和2179例患者ATE事件。VRd组VTE发生率低于KRd组(6.16% vs 8.87%;OR 0.53;95%CI 0.32-0.88;p=.01),两组ATE发生率无显著差异(0.91% vs 1.16%;OR 1.01;95%CI 0.24-4.20;p=.99)。

要点

  • VRd组VTE发生率低于KRd组(6.16% vs 8.87%;OR 0.53;95%CI 0.32-0.88;p=.01)。
  • 两组ATE发生率无显著差异(0.91% vs 1.16%;OR 1.01;95%CI 0.24-4.20;p=.99)。
  • 因回顾性研究偏倚、基线人群异质性及患者水平数据有限,需进一步研究验证。

核心结论

  • VRd组VTE发生率低于KRd组(6.16% vs 8.87%;OR 0.53;95%CI 0.32-0.88;p=.01),两组ATE发生率无显著差异(0.91% vs 1.16%;OR 1.01;95%CI 0.24-4.20;p=.99)。
  • 鉴于回顾性研究潜在偏倚、基线人群特征异质性及患者水平数据获取有限,需进一步研究验证本Meta分析发现并优化多发性骨髓瘤血栓预防策略。

研究设计与样本

  • 比较系统评价与Meta分析,检索去重后共510项研究,最终纳入1项随机对照试验和5项回顾性队列研究。
  • VTE事件分析纳入2304例患者(VRd组1380例;KRd组924例)。
  • ATE事件分析纳入2179例患者(VRd组1316例;KRd组863例)。

主要发现

  • VRd组VTE发生率为6.16%,KRd组为8.87%(OR 0.53;95%CI 0.32-0.88;p=.01)。
  • VRd组ATE发生率为0.91%,KRd组为1.16%,两组无显著差异(OR 1.01;95%CI 0.24-4.20;p=.99)。
  • 两组ATE发生率均较低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 回顾性研究存在潜在偏倚。
  • 基线人群特征存在异质性。
  • 患者水平数据获取有限(如VTE风险分层和所用血栓预防方案类型)。
  • 需进一步研究验证本Meta分析发现并优化多发性骨髓瘤血栓预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombosis represents a frequent and potentially severe complication in individuals diagnosed with multiple myeloma (MM). These events can be driven by both the disease as well as the therapies themselves. Overall, available evidence is inconclusive about the differential thrombogenicity of carfilzomib/lenalidomide/dexamethasone (KRd) and bortezomib/lenalidomide/dexamethasone (VRd). This meta-analysis compares the risk for venous thromboembolism (VTE; including deep venous thrombosis and pulmonary embolism) and arterial thromboembolism (ATE; including myocardial infarction and ischemic stroke) with KRd versus VRd as primary therapy for newly diagnosed MM (NDMM). Out of 510 studies identified after deduplication, one randomized controlled trial and five retrospective cohort studies were included. We analyzed 2304 patients (VRd: 1380; KRd: 924) for VTE events and 2179 patients (VRd: 1316; KRd: 863) for ATE events. Lower rates of VTE were observed in the VRd group when compared with the KRd group (6.16% vs. 8.87%; odds ratio [OR], 0.53; 95% confidence interval [CI], 0.32-0.88; p = .01). Both treatment groups exhibited minimal ATE incidence, with no significant difference between them (0.91% vs. 1.16%; OR, 1.01; 95% CI, 0.24-4.20; p = .99). In view of potential biases from retrospective studies, heterogeneity of baseline population characteristics, and limited access to patient-level data (e.g., VTE risk stratification and type of thromboprophylaxis regimen used) inherent to this meta-analysis, additional research is warranted to further validate our findings and refine strategies for thrombosis prevention in MM.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Costa BA, Costa TA, Saravia SD, et al. Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis. Am J Hematol. 2024. PMID: 38488702. doi:10.1002/ajh.27288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。